Choroidal neovascularization (CNV) in patients with agerelated macular degeneration (ARMD) is the leading cause of irreversible vision loss in the elderly. Neovascularization derived from choroidal blood vessels usually breaks through Bruch's membrane and grows under the retinal pigmented epithelium (RPE). Currently available therapeutic modalities are not highly effi cacious in the treatment of CNV from ARMD. To date, the two treatments shown by large clinical trials to have some effi cacy are thermal laser treatment (photocoagulation) and photodynamic therapy (PDT). Laser photocoagulation is only useful in a small percentage of patients that have well-deÞ ned areas of classic CNV. [1] [2] [3] In addition, central vision is preserved only if these lesions are in either an extrafoveal or juxtafoveal location. Moreover, recurrences aft er laser photocoagulation are common and occur in approximately 50% of patients.
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Photodynamic therapy with verteporÞ n (Visudyne ® , Novartis AG, Basel, Switzerland) has been shown to reduce vision loss for subfoveal CNV secondary to ARMD, particularly if angiography demonstrates the lesion to be predominantly classic CNV. 4 However, many patients have lesions that are not amenable to treatment and vision improvement is unusual.
New treatment modalities that target the neovascularization process including leakage from CNV are currently being developed. Vascular endothelial growth factor has been demonstrated in human specimens of CNV and animal models have conÞ rmed that this protein is capable of inducing CNV. Therefore, targeted inhibition of VEGF seems to be a reasonable approach for the treatment of CNV. VEGF appears to be an important growth factor for angiogenesis and has been shown to be necessary in normal Symposium vascular development. VEGF is highly selective for vascular endothelial cells and induces angiogenesis by serving as a potent endothelial cell mitogen. It has been shown to be secreted by hypoxic RPE cells and induces endothelial cell proliferation and retinal vascular permeability. VEGF has also been shown to be necessary and suffi cient for the development of retinal and iris neovascularization in experimental models. 6 It has been identiÞ ed as a major mediator of retinal ischemiaassociated neovascularization. VEGF is up-regulated by hypoxia and its levels are increased in the vitreous and retina of patients and laboratory animals with active neovascularization from ischemic retinopathies such as proliferative diabetic retinopathy, central retinal vein occlusion and retinopathy of prematurity. Polarized secretion of VEGF by RPE cells is thought to direct VEGF toward the choroidal vasculature, where it may regulate choroidal integrity by binding to its receptors on the adjacent choriocapillaris. The importance of VEGF for the development of ARMD-related CNV has led to the development of strategies to block its eff ects. Such strategies include anti-VEGF antibodies, anti-VEGF aptamer, gene therapy and protein kinase C inhibition. The hope is that blocking the actions of VEGF will prove to be an eff ective strategy for the treatment of CNV. 6 Angiogenesis is the development of new capillaries from preexisting vascular network. It may occur in a variety of ocular disorders, such as retinopathy of prematurity, retinal artery or vein occlusion, diabetic retinopathy and ARMD. The discovery of such factors as VEGF and their mechanisms of action has led to the development of drugs speciÞ cally targeting the molecules or their signal transduction pathways.
7 Rationale VEGF appears to be one of the major regulators in CNV among the angiogenic factors studied so far; VEGF plays a central role in the development of CNV. The VEGF family includes placenta growth factor, VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E. Brieß y, VEGF-A plays a pivotal role in the development of pathologic angiogenesis in ischemic and inß ammatory diseases. VEGF is a 35-to 45-kd homodimeric protein originally isolated as a vasopermeability factor and later cloned and identiÞ ed as an angiogenesis factor. Up to six diff erent VEGF isoforms are derived through alternative splicing of messenger RNA (mRNA). VEGF165 appears to be the isoform most responsible for pathologic ocular neovascularization. Hypoxia is a major regulator of VEGF expression which distinguishes VEGF from other growth factors that have been postulated to have a role in ocular neovascular diseases, including insulin-like growth factor-1, Þ broblast growth factors (FGF), epidermal growth factor and placenta growth factor. Many cells in the eye produce VEGF and within the retina, these include RPE, pericytes, endothelial cells, glial cells, muller cells and ganglion cells. In the human eye, elevated vitreous and aqueous VEGF levels strongly correlate with retinal ischemia-associated neovascularization in conditions like diabetic retinopathy, retinal vein occlusion and retinopathy of prematurity.
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The importance of VEGF as a therapeutic target derives from its roles in two of the most basic processes within a typical lesion of advanced ARMD: neovascularization and vascular leakage. The neovascular form is responsible for 80 to 90% of cases of severe vision loss due to ARMD. Given the increasing prevalence of neovascular ARMD and the burden of associated vision loss, it is important to deÞ ne treatment beneÞ ts that are meaningful to the patient. Neovascular ARMD oft en has a poor prognosis, resulting in a rapid and progressive loss of visual acuity and contrast sensitivity. Such losses have a profound eff ect on patients' quality of life and their ability to perform everyday tasks. Photodynamic therapy, currently the most thoroughly investigated deÞ nitive therapy, is useful mainly for the classic types of neovascular ARMD. However, most angiographic lesions of patients who undergo ß uorescein angiography for neovascular ARMD are subfoveal and occult; only 20% of subfoveal lesions are predominantly classic. Other treatment options such as submacular surgery and steroidbased therapies appear less favorable on current evidence. The strong supportive evidence from animal studies deÞ ned VEGF as an optimal therapeutic target. It is hoped that by using a more selective and less destructive approach, vision loss induced by the treatment itself might be reduced. VEGF over expression induces endothelial cell proliferation and increases vascular permeability, properties that can be detected clinically as the presence of subretinal ß uid or enlarging CNV. Anti-VEGF therapy might reduce subretinal ß uid, a theoretic possibility with VEGF inhibition, 8 resulting in short-term vision improvement.
Mechanism of Action
The role of VEGF as a critical factor in the control of the growth of abnormal blood vessels from the choroid directly att acks a central problem in this disease. The profound vascular permeability induced by VEGF is potentially of even greater importance in the treatment of established neovascular ARMD lesions, in which leakage of ß uid from new vessels causes visual loss through retinal edema and exudation, subretinal ß uid and hemorrhage. Anti-VEGF aptamers are stable small RNA-like molecules that bind exclusively and with high affi nity to the 165-kDa isoform of human VEGF [ Fig. 1 ]. Pegaptanib sodium, an oligonucleotide known as an aptamer, binds and inhibits only the extracellular isoforms of VEGF that are at least 165 amino acids in length.
9 Multiple biologically active forms of VEGF-A are generated by both alternative mRNA splicing and postt ranslational modiÞ cation (proteolytic cleavage), 10 and two of these forms (VEGF165 and VEGF121) have been detected in choroidal neovascular lesions. Pegaptanib (Macugen, PÞ zer) can only bind and inhibit the larger VEGF165 isoform.
In contrast to pegaptanib, bevacizumab (Avastin; Genentech, South San Francisco) a full-length, humanized monoclonal antibody against VEGF and ranibizumab (Lucentis; Genentech, South San Francisco, California), a recombinant, humanized, monoclonal antibody antigen-binding fragment (Fab), bind and neutralize all the biologically active forms of VEGF.
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The similar VEGF binding properties of bevacizumab and ranibizumab can be explained by their common molecular lineage. Both drugs are proteins that were genetically modiÞ ed from the same murine monoclonal antibody against VEGF. The two proteins diff er in their size and affi nity for VEGF. Whereas bevacizumab is a humanized, murine full-length antibody with two binding sites for VEGF, ranibizumab is a humanized, murine antigen-binding fragment (Fab) with only a single affi nity-matured binding site for VEGF.
13 Bevacizumab is currently approved as an intravenous treatment for metastatic colorectal cancer. There is anecdotal evidence that off -label use intravitreal bevacizumab improves short-term visual outcomes in patients with neovascular ARMD. 14 VEGF-Trap(R1R2) is a fusion protein that combines ligandbinding elements taken from the extracellular domains of VEGFR-1 and VEGFR-2 fused to the Fc portion of IgG. This potent high-affinity VEGF blocker effectively suppresses tumor growth and vascularization in vivo, resulting in almost completely avascular tumors. Subcutaneous injections or a single intravitreous injection of VEGF-Trap(R1R2) strongly suppressed CNV in mice with laser-induced rupture of Bruch's membrane, and subretinal neovascularization in transgenic mice expressing VEGF in photoreceptor cells.
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RNAi is a double-stranded piece of interference RNA that is taken up by chorioretinal cells, activating a protein that breaks down the antisense mRNA. Destruction of VEGF mRNA prevents the production of VEGF protein. The whole process is catalytic, so the RNAi may be a very potent and Kim: Anti-vascular endothelial growth factor drugs in ARMD effi cient blockade of VEGF. RNAi may have a long biologic half-life, indicating a much longer interval between intravitreal injections. Anti-VEGF RNAi for the treatment of CNV is currently being tested in clinical trials.
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